Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) covers the month of October 2025, specifically reporting a transaction in the company's own shares executed on October 29, 2025. The filing details a share repurchase conducted through BNP Paribas SA as part of an existing buyback programme established under a non-discretionary agreement announced on September 30, 2025.
Key Financial Metrics and Transaction Details
The filing focuses exclusively on capital allocation via share repurchases rather than operational financial performance. Key metrics for the October 29, 2025 transaction include:
- Shares Purchased: 180,000 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,669.50p; highest price paid was 1,761.00p.
- Average Price: Volume-weighted average price (VWAP) was 1,720.61p.
- Trading Venues: Purchases were executed across XLON (London Stock Exchange), CHIX, and BATE.
Since the programme's restart on September 30, 2025, GSK has purchased an aggregate of 6,948,500 ordinary shares. Following this transaction, the company holds 254,413,344 shares in treasury. The total number of ordinary shares in issue (excluding treasury shares) is 4,061,007,442, representing the total voting rights.
Material Changes and Capital Structure
The primary material change reported is the reduction of shares in issue and the increase in treasury holdings. The percentage of voting rights attributable to ordinary shares held in treasury is now 6.26 per cent. This figure is critical for shareholders calculating their notification thresholds under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules (DTR 5.5.1R). The filing does not report changes in revenue, profit, debt, or liquidity positions.
Guidance, Outlook, and Risks
The filing contains no new operational guidance, earnings outlook, or management commentary regarding business performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks described in GSK's 2024 Annual Report on Form 20-F and Q3 2025 Results. No unusual items or contingencies related to operations are disclosed in this specific filing.
Investor Verification Checklist
- Verify the total number of shares in issue (4,061,007,442) to ensure accurate calculation of ownership percentages for regulatory disclosure purposes.
- Confirm the current treasury share percentage (6.26%) against the company's total authorized share capital limits.
- Review the non-discretionary agreement terms announced on September 30, 2025, to understand the remaining capacity and duration of the buyback programme.
- Check the Q3 2025 Results and 2024 Form 20-F for operational context, as this filing contains no financial performance data.